stockrowLyell Immunopharma, Inc. (LYEL) vs Rezolute, Inc. (RZLT)
- Lyell Immunopharma, Inc. LYEL 14.82 −1.20%
- Rezolute, Inc. RZLT 3.85 +5.77%
Lyell Immunopharma, Inc. and Rezolute, Inc. are both Biotechnology companies. Lyell Immunopharma, Inc. and Rezolute, Inc. are of similar size ($367.6M and $352.1M). Rezolute, Inc. has the higher net margin (0.00% vs −1,701,066.7%) and the higher return on invested capital (0.00% vs −1,070.8%). Across the 13 metrics below, Rezolute, Inc. leads on 9 and Lyell Immunopharma, Inc. on 4.
Valuation
Profitability
| Metric | LYEL | RZLT | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 0.00% | 68.51% |
| Operating margin | (1,783,580.00%) | 0.00% | 0.00% |
| Net margin | (1,701,066.67%) | 0.00% | 0.00% |
| Free cash flow margin | (928,333.33%) | 0.00% | 0.00% |
| Return on equity | (97.79%) | (59.04%) | (51.96%) |
| Return on assets | (74.85%) | (53.82%) | (46.06%) |
| Return on invested capital | (1,070.83%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack